Specifications:
Isotype: IgG2bk
Protein Concentration: > 1.0 mg/ml
Volume/Vial: 100 µl
Storage: 2-8°C
Specificity:
This monoclonal antibody was raised against purified human C9. This antibody has been shown to bind to a neoantigen expressed on SC5b-9, TCC, MAC, poly- C9 and on denatured immobilized C9.
Applications:
Quidel's TCC monoclonal antibody has been used in a variety of experimental techniques including EIA, Western Blot, and Immunohistochemistry.
References:
- Stoltzner, S., Lemerre, C. et al., Temporal accrual of complement proteins in Amyloid plaques in patients with down's syndrome with Alzheimer's Disease, Am J Path 156:489-499, 2000.
- Rogers, J., N. Cooper, et al., Complement Activation by ß-amyloid in Alzheimer disease, PNAS 89:10016-10020, 1992.
- Gemmell, C., A flow cytometric immunoassay to quantify adsorption of complement activation products on artificial surfaces, J Biomed Mater Res 37, 474-480, 1997.
- Depisch, R. V. Schmitt et al., Fluid phase generation of terminal complement complex as a novel index of bio-incompatibility, Kidney Int'l, 37, 696-627 1990.
- S. Merri, Junnikala, S., Exceptional Resistance of Human H2 Gioblastoma Cells to Complement Mediated Killing by Expression and Utilization of Factor H and Factor H Like Protein 1, J Immunol 164:11 6075-6081, 2000.
- Ann Wright, S Morrison., Effect of C2 Associated Carbohydrate structure of Ig Effector function: studies with chimeric mouse human IgG1 Antibodies in glycosylation mutants of chinese hamster ovary cells, J. Immunol 160:3393-3402, 1998.
